CCM
SHPH icon

Connective Capital Management’s Shuttle Pharmaceuticals SHPH Stock Holding History

Connective Capital Management’s Portfolio SHPH Stock Details SHPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-10,054
Closed -$357K – 81
2025
Q3 		$357K Buy
+10,054
New +$376K 0.33% 44

Other funds holding SHPH

IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Connective Capital Management's SHPH Position: Q4 2025 in Review

Connective Capital Management sold out of Shuttle Pharmaceuticals (SHPH) in Q4 2025, closing a stake of 10,054 shares — an estimated $357K sold.

Connective Capital Management first reported a position in SHPH in Q3 2025 and held it in 1 quarter. The position peaked at $357K in Q3 2025. 7 funds tracked by Wall St. Rank hold SHPH as of Q4 2025.

  • Connective Capital Management reported no remaining Shuttle Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Connective Capital Management sold 10,054 Shuttle Pharmaceuticals shares in Q4 2025, an estimated $357K.
  • Connective Capital Management first reported a position in Shuttle Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • Connective Capital Management's Shuttle Pharmaceuticals position peaked at $357K in Q3 2025.
  • 7 funds tracked by Wall St. Rank held Shuttle Pharmaceuticals as of Q4 2025.

Based on Connective Capital Management's 13F filing for Q4 2025, filed 19 Feb 2026.